Bromide

Bromide

SCHEMBL17895414

Br.CCOC(=O)c1csc(NN)n1

nearest known ligand 0.68

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.68
CYP2C19 P33261 1/20 0.68
SMN1; SMN2 Q16637 6/20 0.64
GAA P10253 2/20 0.64
RAB9A P51151 6/20 0.61
NPC1 O15118 5/20 0.61
ALDH1A1 P00352 3/20 0.61
MAPT P10636 2/20 0.61
MEN1 O00255 1/20 0.61
KMT2A Q03164 1/20 0.61
TDP1 Q9NUW8 1/20 0.57
HSP90AA1 P07900 2/20 0.56
MAPK1 P28482 1/20 0.56
KDM4E B2RXH2 3/20 0.54
LMNA P02545 3/20 0.54
HPGD P15428 2/20 0.54
TSHR P16473 1/20 0.54
EGFR P00533 1/20 0.54
MAOA P21397 1/20 0.54
MAOB P27338 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL29010966 1.00 CYP1A2 (0.68) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL4564086 0.98 CYP1A2 (0.69) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL31374393 0.92 CYP1A2 (0.61) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL1816233 0.84 CYP1A2 (0.71) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL13879960 0.83 CYP1A2 (0.69) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL13098582 0.83 CYP1A2 (0.69) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL1536431 0.83 CYP1A2 (0.69) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
Bromide SCHEMBL7142285 0.83 CYP1A2 (0.69) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL13151287 0.82 CYP1A2 (0.48) CYP1A2CYP2C19SMN1; SMN2GAARAB9A
SCHEMBL24248340 0.82 SMN1; SMN2 (0.72) CYP1A2CYP2C19SMN1; SMN2GAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3954685-B1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF US HEALTH (US) 2025-08-27 EP disclosed
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) 2025-07-22 US disclosed
CN-115996924-B Substituted pyrazolyl compounds and methods of use thereof 诺华医药股份公司 2025-03-07 CN disclosed
US-20240368087-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2024-11-07 US disclosed
US-11897845-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-02-13 US disclosed
CN-115996924-A Substituted pyrazolyl compounds and methods of use thereof 奇努克医疗加拿大公司 2023-04-21 CN disclosed
CN-109996797-B 1H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof 美国政府健康及人类服务部 2022-07-22 CN disclosed
US-20220220078-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2022-07-14 US disclosed
CN-107624112-B Small molecule inhibitors of lactate dehydrogenase and methods of use thereof 美国政府健康及人类服务部 2022-03-04 CN disclosed
EP-3954685-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) 2022-02-16 EP disclosed
US-10961200-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2021-03-30 US disclosed
US-10954228-B2 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2021-03-23 US disclosed
US-20190276448-A1 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION 2019-09-12 US disclosed
US-10351532-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2019-07-16 US disclosed
EP-3478677-A1 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF The U.S.A. As Represented By The Secretary, Department Of Health And Human Services (US) 2019-05-08 EP disclosed
US-20180273488-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE UAB RESEARCH FOUNDATION 2018-09-27 US disclosed
CN-107624112-A Small molecule inhibitors of lactate dehydrogenase and methods of use thereof 美国政府健康及人类服务部 2018-01-23 CN disclosed
WO-2018005807-A1 1 H-PYRAZOL-1 -YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2018-01-04 WO disclosed
EP-3240785-A2 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF The United States of America, as represented by The Secretary, Department of Health and Human Services (US) 2017-11-08 EP disclosed
WO-2016109559-A2 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2016-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961200-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHA1 CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885
US-20180273488-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF LDHB, LDHA, PDHB CYP1A2 1803/4885CYP2C19 2531/4885SMN1; SMN2 3369/4885
US-11897845-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHA1 CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885
US-10351532-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHB CYP1A2 1898/4885CYP2C19 2969/4885SMN1; SMN2 3182/4885
US-12365653-B2 Small molecule inhibitors of lactate dehydrogenase and methods of use thereof LDHB, LDHA, PDHA1 CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885
US-20240368087-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF LDHB, LDHA, PDHA1 CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885
US-10954228-B2 1 H-pyrazol-1-yl-thiazoles as inhibitors of lactate dehydrogenase and methods of use thereof PDK1, LDHA, PDK2 CYP1A2 674/4885CYP2C19 689/4885SMN1; SMN2 3434/4885
US-20220220078-A1 SMALL MOLECULE INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF LDHB, LDHA, PDHA1 CYP1A2 1957/4885CYP2C19 2878/4885SMN1; SMN2 3199/4885
US-20190276448-A1 1 H-PYRAZOL-1-YL-THIAZOLES AS INHIBITORS OF LACTATE DEHYDROGENASE AND METHODS OF USE THEREOF PDK1, LDHA, PDK2 CYP1A2 674/4885CYP2C19 689/4885SMN1; SMN2 3434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.